High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study

Nutrients 2020, 12, 3799; doi:10.3390/nu12123799

16 Pages Posted: 18 Feb 2021

See all articles by Stephanie Fenxi Ling

Stephanie Fenxi Ling

The University of Manchester

Eleanor Broad

Tameside and Glossop Integrated Care NHS Foundation Trust

Rebecca Murphy

Tameside and Glossop Integrated Care NHS Foundation Trust

Joseph Mundattuchundayil Pappachan

University of Manchester

Satveer Pardesi-Newton

University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary

Marie-France Kong

University Hospitals of Leicester NHS Trust - Leicester General Hospital

Edward Bernard Jude

Tameside and Glossop Integrated Care NHS Foundation Trust

Date Written: February 16, 2021

Abstract

The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its “parent” form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (ORadj 0.13, 95% CI 0.05–0.35, p < 0.001). This finding was replicated in a validation cohort of 541 patients (ORadj 0.38, 95% CI 0.17–0.84, p = 0.018). In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. Further work with large population studies needs to be carried out to determine adequate serum 25(OH)D levels, as well as multidose clinical trials of cholecalciferol therapy to assess maximum efficacy.

Note: Trial Registration: The study was also registered on Clinicaltrials.gov (reference number NCT04386044), prior to commencement.

Funding: This research received no external funding.

Declaration of Interests: The authors declare no conflict of interest.

Ethics Approval Statement: Ethical approval was granted by the Health and Care Research Wales Research Ethics Committee (IRAS number 285337).

Keywords: SARS-CoV-2; COVID-19; vitamin D; mortality; cholecalciferol; 25-hydroxyvitamin D

JEL Classification: I10

Suggested Citation

Ling, Stephanie Fenxi and Broad, Eleanor and Murphy, Rebecca and Pappachan, Joseph Mundattuchundayil and Pardesi-Newton, Satveer and Kong, Marie-France and Jude, Edward Bernard, High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study (February 16, 2021). Nutrients 2020, 12, 3799; doi:10.3390/nu12123799, Available at SSRN: https://ssrn.com/abstract=3786795

Stephanie Fenxi Ling

The University of Manchester ( email )

Booth St West
Manchester, M15 6PB
United Kingdom

Eleanor Broad

Tameside and Glossop Integrated Care NHS Foundation Trust ( email )

Ashton-under-Lyne
United Kingdom

Rebecca Murphy

Tameside and Glossop Integrated Care NHS Foundation Trust ( email )

Ashton-under-Lyne
United Kingdom

Joseph Mundattuchundayil Pappachan

University of Manchester ( email )

Oxford Road
Manchester, M13 9PL
United Kingdom

Satveer Pardesi-Newton

University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary ( email )

Leicester
United Kingdom

Marie-France Kong

University Hospitals of Leicester NHS Trust - Leicester General Hospital ( email )

United Kingdom

Edward Bernard Jude (Contact Author)

Tameside and Glossop Integrated Care NHS Foundation Trust ( email )

Ashton-under-Lyne
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
176
Abstract Views
1,004
rank
206,485
PlumX Metrics